Pith. sign in

REVIEW 4 major objections 7 minor 6 references

Cartilage-binding antibodies induce pain through immune complex-mediated activation of neurons

T0 review · 4 major / 7 minor · reviewed 2026-08-14 · deepseek-v4-flash

Challenge this review Re-run · record.json Download PDF Read on arXiv ↗ Review JSON

Pith's one-line read Cartilage-binding antibodies cause pain by directly activating Fcγ receptors on sensory nerve endings, independent of joint inflammation.

desk verdict A careful, well-controlled mouse study that convincingly shows cartilage-antibody pain depends on FcγRs, but stops short of proving those FcγRs act on neurons rather than other non-hematopoietic cells. read the letter →

arxiv 1908.05298 v1 pith:HIFGOHF7 submitted 2019-08-08 q-bio.NC q-bio.TO

Alex Bersellini Farinotti , Gustaf Wigerblad , Diana Nascimento , Duygu B Bas , Carlos Morado Urbina , Kutty Selva Nandakumar , Katalin Sandor , Bingze Xu
show 23 more authors
Sally Abdelmoaty Matthew A Hunt Kristina Ängeby Möller Azar Baharpoor Jon Sinclair Kent Jardemark Johanna T Lanner Ia Khmaladze Lars E. Borm Lu Zhang Fredrik Wermeling Mark S Cragg Johan Lengqvist Anne-Julie Chabot-Doré Luda Diatchenko Inna Belfer Mattias Collin Kim Kultima Birgitta Heyman Juan M. Jimenez-Andrade Simone Codeluppi Rikard Holmdahl Camilla I Svensson
This is my paper · ORCID
classification q-bio.NCq-bio.TO
keywords rheumatoidarthritispaincollagentypeIIantibodiesimmunecomplexesFcgammareceptorInociceptorsmechanicalhypersensitivitydorsalrootganglionneuronspreclinicalmodel
verification ladder T0 review T1 audit T2 compute T3 formal

The pith

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The reading

This paper claims that antibodies against cartilage proteins cause pain in mice without first causing inflammation: they meet their antigen in the joint, form immune complexes, and those complexes directly activate pain-sensing nerve fibers through an Fc receptor on the nerve endings. The authors show that mechanical hypersensitivity appears days before any visible, histological, or molecular sign of joint inflammation, is independent of complement, and disappears when activating Fc receptors are missing from neurons or when the antibody's Fc portion is removed or deglycosylated. If correct, this identifies a direct antibody-to-neuron pain pathway that could explain why rheumatoid arthritis patients hurt before and beyond measurable joint inflammation, and points to the immune-complex–FcγRI interaction on sensory neurons as a target for pain treatment.

What carries the argument

The load-bearing mechanism is FcγRI, the high-affinity receptor for the Fc portion of IgG, carried on peripheral endings of nociceptive neurons, and CII-IC, immune complexes made of collagen type II and anti-CII antibody. The paper argues that Fcgr1 mRNA is transported down sensory axons—it accumulates proximal to a sciatic-nerve ligature—so FcγRI can be locally expressed at terminals; when CII-IC engages it, the receptor drives excitatory signaling that raises intracellular calcium, generates an inward current, and releases the pain-associated neuropeptide CGRP. Every intervention that severs the Fc–FcγRI link—Fab fragments, EndoS deglycosylation, FcRγ-chain knockout, or loss of activating FcγRs from non-hematopoietic cells—also abolishes the pain behavior, which is what makes the receptor the pivot of the argument.

What would settle it

In mice with Fcgr1 deleted specifically from nociceptors, systemic anti-CII antibody injection should no longer produce mechanical hypersensitivity if the claim is correct; if such mice still develop hypersensitivity, the neuronal FcγRI requirement is not causal. A complementary observation would be fluorescently labeled CII immune complexes binding to joint-innervating nerve endings in wild-type but not neuron-specific Fcgr1 knockout mice.

Watch

Extended reading notes

Core claim

On its own terms, the paper's central discovery is that collagen type II–reactive antibodies evoke pain-like behavior in mice by forming immune complexes locally in cartilage and activating FcγRI on peripheral sensory-nerve terminals. Preformed CII immune complexes applied to cultured dorsal root ganglion neurons raise intracellular calcium, produce inward currents, and trigger CGRP release, whereas monomeric antibodies do not; neurons from FcRγ-chain-deficient mice do not respond. In vivo, intra-articular injection of CII immune complexes elicits mechanical hypersensitivity in wild-type but not FcRγ-chain-deficient mice, and systemic anti-CII antibodies lose their pronociceptive effect when their Fc interaction is disabled. Chimeric mice lacking activating Fcγ receptors on non-hematopoietic cells, including neurons, are protected from antibody-induced hypersensitivity, which places the relevant receptor on neurons rather than immune cells. The same logic extends to antibodies against cartilage oligomeric matrix protein, supporting the general claim that locally formed immune complexes can drive pain before inflammation begins.

Load-bearing premise

Joint-innervating sensory terminals actually carry functional FcγRI protein that local immune complexes can engage; the paper shows Fcgr1 mRNA moving toward peripheral axons and FcγRI immunoreactivity in skin nerve fibers, but it does not directly demonstrate FcγRI at joint terminals or immune-complex activation of those terminals in vivo.

Editorial extensions

If this is right

  • Pain in autoantibody-driven arthritis can be separated from inflammation: measuring it in the first days after antibody transfer captures a distinct, FcγRI-dependent phase that standard arthritis scoring misses.
  • Blocking FcγRI on peripheral nerve endings, or preventing immune-complex engagement of it, could relieve antibody-induced joint pain without general immunosuppression.
  • The mechanism should generalize to other cartilage and joint antigens: the COMP antibody results show that any antibody that binds an antigen near joint afferents can produce pain once local immune complexes form.
  • In humans the relevant neuronal Fc receptor may be FcγRIII rather than FcγRI, since human DRG neurons express FcγRIII; this makes FcγRIII a candidate target for autoimmune pain.
  • FcRγ-chain-deficient mice become a screening platform for deciding whether other autoantibody-related pain phenotypes depend on activating Fcγ receptors.

Reading between the lines

Editorial extensions of the paper, not claims the author makes directly.

  • Beyond the paper, the same nerve-ending detector could operate in other conditions where antibodies meet local antigen without much inflammation, such as early seropositive arthralgia or crystal-associated arthropathies; this is a testable extension rather than a demonstrated result.
  • The axonal Fcgr1 mRNA transport data suggest local translation at terminals: if true, injuring a nerve or blocking local protein synthesis should change how quickly CII antibodies produce hypersensitivity, a prediction the paper does not test.
  • The roughly one-fifth of cultured neurons responding to CII-IC hints that immune-complex sensing may define a specific nociceptor subpopulation; single-cell profiling could identify molecular markers for that subset.
  • Because the FcγR isoform on neurons differs between species, the mouse data may misidentify the therapeutic target in humans; monoclonal antibodies against human FcγRIII could be screened directly for blockade of IC-evoked human DRG excitation.
Share X Bluesky LinkedIn Reddit HN

Signed reviews

No signed human review yet.

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, and a circularity audit.

Referee Report

4 major / 7 minor

Summary. This manuscript investigates how cartilage-binding autoantibodies cause pain before joint inflammation. Using components of the collagen antibody-induced arthritis (CAIA) model, the authors report that anti-CII monoclonal antibodies elicit mechanical hypersensitivity from day 2 onward, before visual, histological, or molecular signs of inflammation, and that this is independent of complement C5 and cartilage destruction. They map Fcgr mRNA and protein in mouse DRG and peripheral nerve, show that CII immune complexes (CII-ICs) raise intracellular calcium, evoke inward currents, and release CGRP in WT but not FcRγ-chain-deficient DRG cultures, and show that anti-CII/anti-COMP antibodies and preformed ICs induce pain-like behavior in WT but not FcRγ-chain-deficient mice. Bone-marrow chimeras implicate non-hematopoietic FcγRs. The paper concludes that CII-ICs directly activate neuronal FcγRI to produce pain.

Significance. If the causal claim holds, this is a significant conceptual advance: it identifies a pre-inflammatory, non-canonical pathway for autoantibody-induced pain in rheumatoid arthritis and related autoimmune conditions, and it nominates neuronal FcγRs as a therapeutic target. The strengths are substantial: multiple independent readouts (behavior, CGRP release, calcium imaging, patch-clamp electrophysiology), blinded behavioral assessment, isotype and genetic controls including FcRγ-chain-, FcγRIII-, FcγRIV-, and C5-deficient mice, the use of both arthritogenic and non-arthritogenic CII-binding antibodies, Fab and EndoS treatments, and a bone-marrow chimera design. The microarray data are deposited, and public DRG transcriptome resources are used. The principal weakness is that the decisive in vivo genetic experiment does not isolate neurons from other non-hematopoietic cells, and the in vitro experiments do not establish cell-autonomous neuronal signaling; the authors partly acknowledge this in the Discussion.

major comments (4)
  1. [Fig. 8, H–J; Discussion] The in vivo evidence does not establish that sensory neurons, rather than other non-hematopoietic cells, are the FcγR-expressing cells that mediate anti-CII antibody pain. The WT-KO versus KO-WT bone-marrow chimera separates hematopoietic from non-hematopoietic compartments, but the non-hematopoietic compartment also includes keratinocytes, endothelial cells, synovial fibroblasts, and radio-resistant tissue-resident macrophages and mast cells, which can express FcγRs. The authors acknowledge in the Discussion that 'these results do not exclusively test the role of activating FcγRs on neurons,' and the abstract's phrase 'mice lacking activating FcγRs in neurons' is therefore an overstatement. A neuron-specific deletion of Fcgr1 or of the FcR γ-chain (for example with Advillin-Cre or Nav1.8-Cre) is needed to support the title's causal attribution.
  2. [Fig. 6, B–E; Fig. 4, E] The in vitro experiments do not prove that CII-ICs directly activate neurons. CGRP release and calcium imaging were conducted in mixed DRG cultures, and FcRγ-chain deletion removes activating FcγRs from macrophages and satellite glia as well as from neurons; the loss of CGRP release in FcRγ-chain-deficient cultures could therefore reflect loss of non-neuronal FcγR signaling and a secondary mediator. Because FcγRI immunoreactivity in intact DRG is restricted to resident macrophages (Fig. 5, A and B), the positive staining on cultured neurites (Fig. 6 A) needs to be supported by cell-autonomous experiments, such as purified or sorted neuronal cultures, conditioned-medium experiments, or in vitro neuron-specific ablation of FcγR signaling.
  3. [Fig. 5, E–I; Discussion] The paper does not demonstrate FcγRI protein at joint-innervating nerve terminals or local translation of Fcgr1 mRNA in nociceptor axons. FcγRI staining is shown in PGP9.5-positive fibers in glabrous skin, but not in joint afferents, and no FcRγ-chain-knockout negative control is shown for skin immunostaining. The sciatic-ligation smFISH shows accumulation of Fcgr1 and Fcgr2b mRNA proximal to the ligature, but because no axonal marker is provided, accumulation in Schwann cells or recruited macrophages is not excluded. The Discussion states that 'further work is necessary to determine if FcγRs are locally translated in nociceptors,' which is precisely the load-bearing step for the claim that locally formed CII-ICs engage neuronal FcγRI at peripheral terminals.
  4. [Fig. 6, D and E; Fig. 7, I–K] The attribution to FcγRI specifically is made by exclusion (FcγRIII deficiency does not alter calcium responses, and FcγRIV-deficient mice still develop pain), but no FcγRI-specific loss-of-function or blocking reagent is used. Since FcRγ-chain deletion removes FcγRI, FcγRIII, and FcγRIV together, the conclusion that FcγRI is the responsible receptor would be strengthened by an FcγRI-blocking antibody, Fcgr1 knockdown in cultured neurons, or conditional Fcgr1 deletion.
minor comments (7)
  1. [Abstract] The phrase 'mice lacking activating FcγRs in neurons' should be changed to 'mice lacking activating FcγRs in non-hematopoietic cells' until a neuron-specific manipulation is performed.
  2. [Fig. 5, E and F] Please add FcRγ-chain-knockout skin sections as a specificity control for the FcγRI and FcγRIIb immunoreactivity in nerve fibers.
  3. [Fig. 5, H and I] Please include a neuronal or axonal marker (for example neurofilament or SCG10) in the sciatic-ligation smFISH to support the interpretation of axonal mRNA transport.
  4. [Methods, Calcium imaging and Electrophysiology] Please report the number of independent cultures and animals, and the number of cells per group, for the calcium-imaging and patch-clamp experiments; the text gives aggregate cell counts but not the replicate structure.
  5. [Results, Fig. 6 B] The phrase 'directly activate cultured WT... DRG neurons' is too strong for a mixed-culture preparation; consider 'activate DRG neurons in mixed cultures' until cell-autonomy is demonstrated.
  6. [Discussion, human DRG] The human data show FcγRIII, not FcγRI, in DRG neurons; the translational discussion should more clearly separate the mouse FcγRI mechanism from the human FcγRIII observation, which is purely descriptive.
  7. [Fig. 8, H–J; Methods] The labels WT-KO and KO-WT are easy to misread; please spell out donor genotype into recipient genotype in the figure legend and define the direction of the bone-marrow transfer explicitly.

Circularity Check

0 steps flagged · score 0.0 of 10

No circularity found: the central claim is tested by independent genetic loss-of-function, behavioral, and in vitro assays, not derived from its own inputs.

full rationale

The load-bearing chain is: anti-CII/COMP antibodies form immune complexes in joints; FcγRI is present on peripheral sensory axons; CII-ICs excite WT but not FcRγ-chain-deficient DRG neurons; and anti-CII antibodies fail to induce mechanical hypersensitivity in FcRγ-chain-deficient mice and in chimeras lacking activating FcγRs on non-hematopoietic cells. Each link is supported by external readouts (von Frey thresholds, locomotion, CGRP release, calcium imaging, patch clamp) and by genetic loss-of-function models rather than by fitting a parameter to the outcome. The authors' prior work supplies reagents (anti-CII mAb cocktail, CAIA model, EndoS treatment, CIIF4 non-arthritogenic antibody) and background observations, but the present predictions do not reduce to those prior results by definition. The Discussion explicitly acknowledges the residual ambiguity of the chimera experiment ('these results do not exclusively test the role of activating FcγRs on neurons') and the lack of proof of local translation ('While further work is necessary to determine if FcγRs are locally translated in nociceptors'); these are honest scope limits, not circular reasoning. No equation, fitted parameter, or self-citation chain makes the conclusion equivalent to an input.

Assumptions & free parameters 0 free parameters · 4 assumptions · 0 invented entities

The paper relies on established reagents and genetic models; there are no fitted free parameters. The main assumptions are domain-specific: the specificity of the FcR gamma-chain knockout, the formation and accessibility of immune complexes in the joint after i.v. antibody injection, the clean separation of cell types by bone-marrow chimeras, and the interpretation of reflex withdrawal as pain-like behavior. Each is reasonable and supported by prior literature, but none is directly validated within this study.

assumptions (4)
  • domain assumption FcR gamma-chain knockout eliminates cell surface expression and signaling of activating Fc gamma receptors I, III, and IV, while leaving Fc gamma receptor IIb intact.
    This is the key genetic tool used for in vivo and in vitro attribution to activating Fc gamma receptors; the paper relies on Takai et al. 1994 and Nimmerjahn et al. 2005 rather than re-validating the line phenotypically.
  • domain assumption Intravenously injected anti-CII antibodies reach the joint and form local immune complexes with CII fragments in the synovium or cartilage.
    The proposed mechanism requires local immune complex formation in the joint; the paper cites Jonsson et al. 1989 for cartilage binding and Lohmander et al. 2003 for synovial CII fragments, but does not directly detect CII-ICs in the joint in this study.
  • domain assumption Bone-marrow chimeras separate hematopoietic from non-hematopoietic Fc gamma receptor expression without confounding radiation damage to peripheral neurons.
    The WT-KO versus KO-WT comparison underpins the conclusion that Fc gamma receptors on non-hematopoietic cells (including neurons) are required; no chimerism percentage or neuron-health validation is reported.
  • domain assumption Mechanical withdrawal thresholds measured with von Frey filaments reflect pain-like behavior rather than motor impairment or general debilitation.
    The paper includes an inverted grid test to control for grip strength, but the reflex measure remains a surrogate for pain.

how reviews work

0 comments
Cite this review

Pith. "Pith review of Cartilage-binding antibodies induce pain through immune complex-mediated activation of neurons." pith.science (2026). https://pith.science/paper/HIFGOHF7

@misc{pith2026190805298,
  author       = {Pith},
  title        = {Pith review of: Cartilage-binding antibodies induce pain through immune complex-mediated activation of neurons},
  year         = {2026},
  howpublished = {\url{https://pith.science/paper/HIFGOHF7}},
  note         = {Machine review of arXiv:1908.05298}
}
read the original abstract

Rheumatoid arthritis-associated joint pain is frequently observed independent of disease activity, suggesting unidentified pain mechanisms. We demonstrate that antibodies binding to cartilage, specific for collagen type II (CII) or cartilage oligomeric matrix protein (COMP), elicit mechanical hypersensitivity in mice, uncoupled from visual, histological and molecular indications of inflammation. Cartilage antibody-induced pain-like behavior does not depend on complement activation or joint inflammation, but instead on tissue antigen recognition and local immune complex (IC) formation. smFISH and IHC suggest that neuronal Fcgr1 and Fcgr2b mRNA are transported to peripheral ends of primary afferents. CII-ICs directly activate cultured WT but not FcR{\gamma} chain-deficient DRG neurons. In line with this observation, CII-IC does not induce mechanical hypersensitivity in FcR{\gamma} chain-deficient mice. Furthermore, injection of CII antibodies does not generate pain-like behavior in FcR{\gamma} chain-deficient mice or mice lacking activating Fc{\gamma}Rs in neurons. In summary, this study defines functional coupling between autoantibodies and pain transmission that may facilitate the development of new disease-relevant pain therapeutics.

Figures

Figures reproduced from arXiv: 1908.05298 by the authors.

Figure 2
Figure 2. Anti-CII antibodies injected either as a cocktail or as individual antibodies induce mechanical hypersensitivity and reduce locomotion before inflammation. (A–C) Anti-CII mAbs (n = 10) induced mechanical hypersensitivity as early as 2 d after injection (A) compared with saline controls (n = 9) in B10.RIII mice. Arthritis scores (B) and incidence (C) were not detectable until day 4 and remained very low also on day 5… view at source ↗
Figure 4
Figure 4. FcγRs are expressed in mouse DRG neurons. (A) Microarray data showed mRNA for Fcgr1–4 in CBA mouse DRG (n = 3). (B) Quantitative PCR showed mRNA for Fcgr1–4 in B10.RIII mouse DRG (n = 10). (C) Publicly available RNA sequencing of C57BL/6 mouse DRGs show the presence for Fcgr1–4 (n = 3). (D) smFISH showed mRNA molecules for Fcgr1, Fcgr2b, and Fcgr3 in BALB/c mouse DRG colocalizing with NeuN. Scatter graph shows numbe… view at source ↗
Figure 5
Figure 5. FcγRI and FcγRIIb are expressed in the DRG and in nerve fibers in the skin. (A and B) FcγRI immunoreactivity was detected in WT BALB/c DRGs, but not in FcRγ-chain−/− mice (A), colocalizing with Iba1-positive resident macrophages (B). Scale bars represent 100 µm and 50 µm, respectively. (C and D) FcγRIIb immunoreactivity was detected in BALB/c mouse DRG and retained in FcRγ-chain−/− mice (C), colocalizing with TrkA-p… view at source ↗
Figures from the paper (4 more)
Figure 6
Figure 6. Figure 6: CII-IC stimulation of DRG cell cultures leads to increased neuronal excitability. (A) FcγRI and FcγRIIb are expressed in BALB/c mouse DRG neurons in culture as shown by colocalization with βIII-tubulin. Scale bars represent 10 µm. (B and C) CII-IC stimulation of BALB/c…
Figure 7
Figure 7. Figure 7: Different ICs promote pain-like behavior in vivo, and FcγRIV−/− mice develop mechanical hypersensitivity despite lack of CAIA. (A and B) I.a. injection of CII-IC–induced mechanical hypersensitivity in WT BALB/c mice (n = 14–21/group; A) but not in FcRγ-chain−/− mice (n…
Figure 8
Figure 8. Figure 8: The pronociceptive properties of anti-CII antibodies are dependent on the Fc region, glycosylation, and interaction with FcγRI in the joint. (A–C) B10.RIII mice injected with anti-CII mAb Fab fragments (n = 8) did not develop mechanical hypersensitivity (day 5; A) comp…
Figure 9
Figure 9. Figure 9: FcγRI and FcγRIII are expressed in human DRG. (A) Publicly available data show the presence of Fcgr mRNA in human DRGs (n = 6). Fcgr3a is the most highly expressed. (B and C) FcγRI immunoreactivity was detected in human DRGs (n = 4). The lack of colocalization with Neu…

Discussion (0). Continue with ORCID to comment.

Reference graph

Works this paper leans on

6 extracted references · 5 canonical work pages

  1. [6]

    Karlsson, and R

    https://doi .org/10.1002/1521-4141(200106)31:6<1847::AID-IMMU1847>3.0.CO;2-F Jonsson, R., A.L. Karlsson, and R. Holmdahl. 1989. Demonstration of immu- noreactive sites on cartilage after in vivo administration of biotinylated anti-type II collagen antibodies. J. Histochem. Cytochem. 37:265– 268. https://doi.org/10.1177/37.2.2911008 Klein, C.J., V.A. Lenno...

    work page doi:10.1002/1521-4141(200106)31:6 1989

  2. [1623]

    Bruhns, K

    https://doi.org/10.3389/fimmu.2018.01623 Nimmerjahn, F., P. Bruhns, K. Horiuchi, and J.V. Ravetch. 2005. Fcgam- maRIV: a novel FcR with distinct IgG subclass specificity. Immunity. 23: 41– 51. https://doi.org/10.1016/j.immuni.2005.05.010 Nimmerjahn, F., A. Lux, H. Albert, M. Woigk, C. Lehmann, D. Dudziak, P. Smith, and J.V. Ravetch. 2010. Fc γRIV deletion...

    work page arXiv 2018

  3. [1985]

    Disappearing collagen antibodies in rheumatoid arthritis. Lancet. 2:501– 502. https://doi.org/10.1016/S0140-6736(85)90436-2 Price, T.J., and S.M. G ´eranton. 2009. Translating nociceptor sensitivity: the role of axonal protein synthesis in nociceptor physiology.Eur. J. Neurosci. 29:2253– 2263. https://doi.org/10.1111/j.1460-9568.2009.06786.x Qu, L., P. Zh...

    arXiv 2009

  4. [1992]

    Induction of arthritis with monoclonal antibodies to collagen. J. Immunol. 148:2103– 2108. Tutt, A.L., S. James, S.A. Laversin, T.R. Tipton, M. Ashton-Key, R.R. French, K. Hussain, A.T. Vaughan, L. Dou, A. Earley, et al. 2015. Development and Characterization of Monoclonal Antibodies Specific for Mouse and Human Fc γ Receptors. J. Immunol. 195:5503– 5516....

    work page 2015

  5. [2010]

    Patient perceptions concerning pain management in the treat- ment of rheumatoid arthritis. J. Int. Med. Res. 38:1213– 1224. https://doi .org/10.1177/147323001003800402 Terato, K., K.A. Hasty, R.A. Reife, M.A. Cremer, A.H. Kang, and J.M. Stuart

    work page doi:10.1177/147323001003800402

  6. [2013]

    Voluntary movements as a possible non-reflexive pain assay.Mol. Pain. 9:25. https://doi.org/10.1186/1744-8069-9-25 Clague, R.B., and L.J. Moore. 1984. IgG and IgM antibody to native type II col- lagen in rheumatoid arthritis serum and synovial fluid. Evidence for the presence of collagen-anticollagen immune complexes in synovial fluid. Arthritis Rheum.27:...

    work page doi:10.1186/1744-8069-9-25 1984

Pith tools

Reviewed August 14, 2026 · model on record in the stance chip above.